physician web portal

Healthcare Professionals

Gastroenterology

Divider

Hematology/Oncology

The AmeriPath Difference

Professional Staff

Resource Committee

Test Menu

News/Events

Connectivity Solutions

Divider

Urology

Divider

Women's Health

Divider

Dermatopathology

Divider

Subspecialties

Divider

Managed Care

Divider

Labs/Locations

TEST MENU

Cytochrome P450 2C9 and VKORC1 (Warfarin) Mutation Analysis

Method	Units	Reference Range
PCR

Specimen Requirements

Preferred
No	Type	Volume	Temperature/Stability
1	Whole blood EDTA (purple top)	5 mL	Ambient - 7 days Refrigerated - 7 days
Alternate
No	Type	Volume	Temperature/Stability
1	Whole blood ACD (yellow top)	3-5 mL	Ambient - 7 days Refrigerated - 7 days

General Information

Clinical Utility	Warfarin (coumadin) therapy is associated with significant complications because of its narrow therapeutic index and large interpatient dosage variation necessary to achieve an optimal therapeutic response. This variation is due to both genetic and environmental factors. A promoter variant (-1639 G>A) of the vitamin K epoxide complex subunit 1 (VKORC1) account for 25 to 44 percent of this variability and variants of the cytochrome P450 enzyme 2C9 (CYP 2C9) account for 10 to 15 percent of this variability. Identification of these warfarin sensitive variants of the VKORC1 and CYP 2C9 genes may allow a more individualized therapy and reduced risk of bleeding complications.
Set Up Schedule
Turnaround Time
CPT Codes	83891, 83900, 83901x4, 83896x5, 83909, 83912
FDA Status	ASR
Notes
References

Copyright © 2010 AmeriPath, Inc.®

For Our Associates

san francisco web design and database development